ARWR - Arrowhead Pharmaceuticals, Inc.
NEXT EARNINGS:
May 11, 2026
EPS Est: $-1.04
|
Rev Est: $66.6M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$78.78
DETAILS
HIGH:
$110.00
LOW:
$35.00
MEDIAN:
$80.00
CONSENSUS:
$78.78
UPSIDE:
23.73%
Market Cap:
8.92B
Volume:
2,391,755
Avg Volume:
3,181,218
52 Week Range:
9.57-76.76
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.22
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
609
IPO Date:
1993-12-16
EPS (TTM):
-0.01
P/E Ratio:
-2828.52
Revenue (TTM):
829.45M
Total Assets:
1.39B
Total Debt:
366.28M
Cash & Equiv:
226.55M
Rev Growth (5Y):
56.6%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
45.2%
ROCE:
11.8%
Debt/Equity:
0.79
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-05 | $0.22 | $0.60 | -63.3% | $264.0M | $66.6M | +296.7% |
| 2025-11-25 | $-0.18 | $-0.11 | -61.3% | $256.5M | $175.3M | +46.3% |
| 2025-08-07 | $-1.26 | $-0.94 | -34.0% | $27.8M | $154.1M | -82.0% |
| 2025-05-12 | $2.75 | $-0.06 | +4683.3% | $542.7M | $116.3M | +366.8% |
| 2025-02-10 | $-1.39 | $-0.42 | -231.0% | $2.5M | $19.1M | -86.9% |
| 2024-11-26 | $-1.38 | $-1.05 | -31.4% | $3.6M | $55.1M | -93.6% |
| 2024-08-08 | $-1.38 | $-0.58 | -137.9% | — | $69.7M | — |
| 2024-05-09 | $-1.02 | $-0.06 | -1600.0% | — | $63.9M | — |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 829.45M | 3.55M | 240.74M | 243.23M | 138.29M | 87.99M | 168.80M | 16.14M | 31.41M | 158,333 | 382,000 | 175,000 |
| Net Income | (1.63M) | (599.49M) | (205.28M) | (176.06M) | (140.85M) | (84.55M) | 67.97M | (54.45M) | (34.38M) | (81.72M) | (91.94M) | (58.63M) |
| EPS | -0.01 | -5.00 | -1.91 | -1.67 | -1.36 | -0.84 | 0.72 | -0.65 | -0.47 | -1.34 | -1.60 | -1.25 |
| Total Assets | 1.39B | 1.14B | 765.55M | 691.94M | 710.15M | 522.50M | 349.85M | 111.61M | 104.02M | 128.18M | 132.27M | 182.82M |
| Total Debt | 366.28M | 851.91M | 383.50M | 81.58M | 25.55M | 21.14M | 0 | 2.33M | 2.53M | 2.73M | 758,340 | 1.02M |
| Cash & Equivalents | 226.55M | 102.69M | 110.89M | 108.00M | 184.43M | 143.58M | 221.80M | 30.13M | 24.84M | 85.37M | 81.21M | 132.51M |
| Operating Cash Flow | 179.55M | (462.85M) | (153.89M) | (136.13M) | 171.22M | (95.39M) | 173.03M | (47.22M) | (23.94M) | (64.43M) | (65.71M) | (35.42M) |
| Free Cash Flow | 156.89M | (604.32M) | (330.63M) | (188.91M) | 147.66M | (107.34M) | 161.03M | (48.64M) | (31.86M) | (68.29M) | (67.68M) | (37.13M) |
| FCF per Share | 1.17 | -5.05 | -3.08 | -1.79 | 1.42 | -1.07 | 1.72 | -0.58 | -0.44 | -1.12 | -1.18 | -0.79 |
| Book Value | 466.05M | 185.44M | 271.34M | 398.52M | 408.82M | 461.78M | 244.59M | 95.80M | 81.42M | 95.58M | 110.18M | 166.54M |
| Cash & ST Investments | 919.37M | 680.96M | 403.63M | 376.40M | 367.79M | 315.49M | 258.70M | 76.53M | 65.61M | 85.37M | 98.75M | 154.16M |
| ROC Equity | -0.00 | -3.23 | -0.76 | -0.44 | -0.34 | -0.18 | 0.28 | -0.57 | -0.42 | -0.86 | -0.83 | -0.35 |